OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
FDA Approvals Expand Treatment Options for Breast and Lung Cancers

FDA Approvals Expand Treatment Options for Breast and Lung Cancers

by FDA Approval | 30 September 2024 | Lung Cancer, Women's Cancers

The U.S. Food and Drug Administration (FDA) has made significant advancements in cancer treatment by approving multiple new therapies across breast and lung cancer. These approvals promise to expand treatment options and improve outcomes for patients with these...
European Commission Approves New Treatments for Urothelial and Lung Cancer

European Commission Approves New Treatments for Urothelial and Lung Cancer

by EMA Approval | 30 August 2024 | Lung Cancer, Urogenital

The European Commission has approved two new cancer treatments: enfortumab vedotin in combination with pembrolizumab for urothelial cancer and amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer (NSCLC). These approvals mark significant...
FDA Approves New Treatments for Non-Small Cell Lung Cancer

FDA Approves New Treatments for Non-Small Cell Lung Cancer

by FDA Approval | 21 August 2024 | Lung Cancer

The Food and Drug Administration (FDA) granted approval for durvalumab and the combination of lazertinib with amivantamab-vmjw as innovative treatments for non-small cell lung cancer (NSCLC). These approvals represent a major advancement in the battle against this...
Celebrating Breakthroughs in Lung Cancer Treatment on World Lung Cancer Day

Celebrating Breakthroughs in Lung Cancer Treatment on World Lung Cancer Day

by PEAK Medicals | 1 August 2024 | Lung Cancer

On World Lung Cancer Day, it’s important for us to reflect on the recent advancements in lung cancer treatment that are reshaping patient care and outcomes. The landscape of lung cancer therapy is rapidly evolving, driven by cutting-edge research and innovative...
Swissmedic Approves Alectinib In Early Stage ALK+ NSCLC

Swissmedic Approves Alectinib In Early Stage ALK+ NSCLC

by Swiss Approval | 26 July 2024 | Lung Cancer

Alectinib has been approved by the Swissmedic as a monotherapy for adjuvant treatment in adult patients with ALK-positive stage IB (tumor ≥4cm) to IIIA non-small cell lung cancer after complete tumor resection. The recommended dose is 600 mg twice daily. It is...
Swissmedic Approves Durvalumab for Perioperative Treatment of Resectable NSCLC

Swissmedic Approves Durvalumab for Perioperative Treatment of Resectable NSCLC

by Swiss Approval | 4 July 2024 | Lung Cancer

Durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, has received approval from Swissmedic for the treatment of adult patients with resectable NSCLC (tumours ≥4 cm and/or positive...
« Older Entries
Next Entries »

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}